Biosimilar Versus Patented Erythropoietins: Learning from 5 Years of European and Japanese Experience
Crossref DOI link: https://doi.org/10.1007/s40258-014-0125-6
Published Online: 2014-09-05
Published Print: 2015-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Bocquet, François
Paubel, Pascal
Fusier, Isabelle
Cordonnier, Anne-Laure
Sinègre, Martine
Le Pen, Claude
Text and Data Mining valid from 2014-09-05